Literature DB >> 20230905

Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.

Jonathan M Flanagan1, Thad A Howard, Nicole Mortier, Svetlana L Avlasevich, Matthew P Smeltzer, Song Wu, Stephen D Dertinger, Russell E Ware.   

Abstract

Hydroxyurea induces fetal hemoglobin, improves laboratory parameters, and ameliorates clinical complications of sickle cell anemia (SCA), but its long-term efficacy and safety in this patient population remain incompletely defined. Although generally considered non-DNA reactive, an important safety concern is that hydroxyurea may indirectly cause genotoxic damage. To better address this safety issue of hydroxyurea in patients with SCA, we measured the production of micronuclei (MN) in red blood cells (RBCs) as a marker of genotoxicity. Blood samples were collected from children with SCA enrolled in the Hydroxyurea Study of Long-term Effects (ClinicalTrials.gov NCT00305175). Flow cytometry quantified circulating MN-containing erythrocyte sub-populations before and during hydroxyurea exposure. The frequency of micronucleated reticulocytes (MN-CD71(+)) and micronucleated mature erythrocytes (MN-RBC) was then tested for associations with laboratory and clinical data. In cross-sectional analysis of 293 blood samples from 105 children with SCA and a median of 2 years of hydroxyurea therapy, exposure to hydroxyurea was associated with significantly increased frequencies of MN-CD71(+) and MN-RBC compared to baseline. The increases were evident by 3 months of therapy, and did not escalate further with up to 12 years of continuous drug exposure. In prospective longitudinal analysis, substantial inter-individual variation in the effect of hydroxyurea on %MN-CD71(+) was observed that was associated with the expected laboratory effects of hydroxyurea. In conclusion, clinically relevant exposure to hydroxyurea is associated with increased MN production consistent with erythroblast genotoxicity but with substantial inter-patient variability. Associations between increased %MN-CD71(+) and laboratory benefits suggest that hydroxyurea effects on MN production may be related to individual patient sensitivity to hydroxyurea within the bone marrow. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20230905      PMCID: PMC5831106          DOI: 10.1016/j.mrgentox.2010.03.001

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  26 in total

1.  The effect of inhibited replication on DNA migration in the comet assay in relation to cytotoxicity and clastogenicity.

Authors:  Günter Speit; Petra Schütz
Journal:  Mutat Res       Date:  2008 Aug-Sep       Impact factor: 2.433

2.  Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

Authors:  Jane S Hankins; Russell E Ware; Zora R Rogers; Lynn W Wynn; Peter A Lane; J Paul Scott; Winfred C Wang
Journal:  Blood       Date:  2005-10-01       Impact factor: 22.113

3.  Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; F B Barton; R D Moore; M L Terrin; M H Steinberg; G J Dover; S K Ballas; R P McMahon; O Castro; E P Orringer
Journal:  Medicine (Baltimore)       Date:  1996-11       Impact factor: 1.889

4.  Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Authors:  T R Kinney; R W Helms; E E O'Branski; K Ohene-Frempong; W Wang; C Daeschner; E Vichinsky; R Redding-Lallinger; B Gee; O S Platt; R E Ware
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

5.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

Review 6.  Hydroxyurea for children with sickle cell disease.

Authors:  Matthew M Heeney; Russell E Ware
Journal:  Pediatr Clin North Am       Date:  2008-04       Impact factor: 3.278

7.  Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells.

Authors:  K Ziegler-Skylakakis; L R Schwarz; U Andrae
Journal:  Mutat Res       Date:  1985 Nov-Dec       Impact factor: 2.433

8.  Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.

Authors:  A Ferster; C Vermylen; G Cornu; M Buyse; F Corazza; C Devalck; P Fondu; M Toppet; E Sariban
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

Review 9.  Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.

Authors:  F M Gill; L A Sleeper; S J Weiner; A K Brown; R Bellevue; R Grover; C H Pegelow; E Vichinsky
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

10.  Micronucleated CD71-positive reticulocytes: a blood-based endpoint of cytogenetic damage in humans.

Authors:  Stephen D Dertinger; Yuhchyau Chen; Richard K Miller; Kelly J Brewer; Therese Smudzin; Dorothea K Torous; Nikki E Hall; Kristine A Olvany; Francis G Murante; Carol R Tometsko
Journal:  Mutat Res       Date:  2003-12-09       Impact factor: 2.433

View more
  25 in total

1.  Effects of hydroxyurea on CNV induction in the mouse germline.

Authors:  Martin F Arlt; Sountharia Rajendran; Sandra N Holmes; Kathleen Wang; Ingrid L Bergin; Samreen Ahmed; Thomas E Wilson; Thomas W Glover
Journal:  Environ Mol Mutagen       Date:  2018-09-15       Impact factor: 3.216

2.  Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.

Authors:  Samuel Regan; Xuebin Yang; Niklas K Finnberg; Wafik S El-Deiry; Jeffrey J Pu
Journal:  Cancer Biol Ther       Date:  2019-08-18       Impact factor: 4.742

3.  Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.

Authors:  Patrick T McGann; Jonathan M Flanagan; Thad A Howard; Stephen D Dertinger; Jin He; Anita S Kulharya; Bruce W Thompson; Russell E Ware
Journal:  Pediatr Blood Cancer       Date:  2011-10-19       Impact factor: 3.167

4.  The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.

Authors:  Shuaiying Cui; Kim-Chew Lim; Lihong Shi; Mary Lee; Natee Jearawiriyapaisarn; Greggory Myers; Andrew Campbell; David Harro; Shigeki Iwase; Raymond C Trievel; Angela Rivers; Joseph DeSimone; Donald Lavelle; Yogen Saunthararajah; James Douglas Engel
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

Review 5.  Replication stress and mechanisms of CNV formation.

Authors:  Martin F Arlt; Thomas E Wilson; Thomas W Glover
Journal:  Curr Opin Genet Dev       Date:  2012-02-23       Impact factor: 5.578

6.  Hydroxyurea induces de novo copy number variants in human cells.

Authors:  Martin F Arlt; Alev Cagla Ozdemir; Shanda R Birkeland; Thomas E Wilson; Thomas W Glover
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

7.  Response kinetics of radiation-induced micronucleated reticulocytes in human bone marrow culture.

Authors:  Hongliang Sun; Ying Tsai; Irena Nowak; Stephen D Dertinger; J H David Wu; Yuhchyau Chen
Journal:  Mutat Res       Date:  2010-11-04       Impact factor: 2.433

8.  Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Authors:  Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson
Journal:  Lancet       Date:  2011-05-14       Impact factor: 79.321

9.  Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.

Authors:  Russell E Ware; Jenny M Despotovic; Nicole A Mortier; Jonathan M Flanagan; Jin He; Matthew P Smeltzer; Amy C Kimble; Banu Aygun; Song Wu; Thad Howard; Alex Sparreboom
Journal:  Blood       Date:  2011-08-29       Impact factor: 22.113

Review 10.  Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?

Authors:  Patrick T McGann; Russell E Ware
Journal:  Curr Opin Hematol       Date:  2011-05       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.